<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595854</url>
  </required_header>
  <id_info>
    <org_study_id>1160.141</org_study_id>
    <secondary_id>2012-000874-42</secondary_id>
    <nct_id>NCT01595854</nct_id>
  </id_info>
  <brief_title>Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran</brief_title>
  <official_title>Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new
      pharmacodynamic methods
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Dabigatran: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
    <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related Adverse Events</measure>
    <time_frame>From screening until the end-of-study examination</time_frame>
    <description>The number of participants with drug related adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test 2 (part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose dabigatran + high dose ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 1 (part 1 + 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1 (part 1 + 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2 (part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose dabigatran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>medium dose dabigatran</description>
    <arm_group_label>Reference 1 (part 1 + 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>high dose ticagrelor</description>
    <arm_group_label>Test 1 (part 1 + 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>high dose ticagrelor</description>
    <arm_group_label>Test 2 (part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>low dose dabigatran</description>
    <arm_group_label>Reference 2 (part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>medium dose dabigatran</description>
    <arm_group_label>Test 2 (part 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

             Exclusion criteria:

          2. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.141.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>June 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2013</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate 220 mg - Part 1</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a washed blood test.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor 180 mg - Part 1</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a washed blood test.</description>
        </group>
        <group group_id="P3">
          <title>Dabigatran Etexilate 220 mg - Part 2</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a shed blood test.</description>
        </group>
        <group group_id="P4">
          <title>Ticagrelor 180 mg - Part 2</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a shed blood test</description>
        </group>
        <group group_id="P5">
          <title>Dabigatran Etexilate/Multiple Dose Ticagrelor Crossover-Part 3</title>
          <description>A randomised, two-period, cross-over trial, the two treatments administered were
A single dose of dabigatran etexilate 75 mg
Ticagrelor coated tablets dosed for four days; 180 mg loading dose on day 1, 90 mg twice daily on day 2 and 3, 90 mg on day 4. Co-administered is a single dose of 75 mg Dabigatran etexilate on days 1 and 4.
Between treatment periods there was a washout period of at least 4 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran Etexilate 220 mg - Part 1</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a washed blood test.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor 180 mg - Part 1</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a washed blood test.</description>
        </group>
        <group group_id="B3">
          <title>Dabigatran Etexilate 220 mg - Part 2</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a shed blood test.</description>
        </group>
        <group group_id="B4">
          <title>Ticagrelor 180 mg - Part 2</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a shed blood test</description>
        </group>
        <group group_id="B5">
          <title>Dabigatran Etexilate / Multiple Dose Ticagrelor - Part 3</title>
          <description>A randomised two-period cross-over trial, the two treatments administered were
A single dose of dabigatran etexilate 75 mg
Ticagrelor coated tablets dosed for four days; 180 mg loading dose on day 1, 90 mg twice daily on day 2 and 3, 90 mg on day 4. Co-administered with a single dose of 75 mg Dabigatran etexilate on days 1 and 4.
Between treatment periods there was a washout period of at least 4 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="7.7"/>
                    <measurement group_id="B2" value="29.8" spread="11.4"/>
                    <measurement group_id="B3" value="33.6" spread="9.1"/>
                    <measurement group_id="B4" value="33.3" spread="6.3"/>
                    <measurement group_id="B5" value="30.2" spread="7.2"/>
                    <measurement group_id="B6" value="31.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.</description>
        <time_frame>-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
        <population>Pharmacokinetic (PK) set defined as all subjects of Part 3 who received at least 1 dose of trial medication and provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabi 75 mg</title>
            <description>A single dose of Dabigatran etexilate (Dabi) 75 mg.</description>
          </group>
          <group group_id="O2">
            <title>Dabi + Ticagrelor LD</title>
            <description>A single dose of 75 mg Dabigatran coadministered with a loading dose (LD) of 180 mg ticagrelor coated tablets (T).</description>
          </group>
          <group group_id="O3">
            <title>Dabi + Ticagrelor MD</title>
            <description>A single dose of 75 mg Dabigatran coadministered with a morning dose of multiple dose (MD) ticagrelor.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.</description>
          <population>Pharmacokinetic (PK) set defined as all subjects of Part 3 who received at least 1 dose of trial medication and provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.05" spread="104"/>
                    <measurement group_id="O2" value="485.48" spread="40.5"/>
                    <measurement group_id="O3" value="410.46" spread="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Dabigatran: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
        <time_frame>-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
        <population>Pharmacokinetic (PK) set defined as all subjects of Part 3 who received at least 1 dose of trial medication and provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabi 75 mg</title>
            <description>A single dose of Dabigatran etexilate (Dabi) 75 mg.</description>
          </group>
          <group group_id="O2">
            <title>Dabi + Ticagrelor LD</title>
            <description>A single dose of 75 mg Dabigatran coadministered with a loading dose (LD) of 180 mg ticagrelor coated tablets (T).</description>
          </group>
          <group group_id="O3">
            <title>Dabi + Ticagrelor MD</title>
            <description>A single dose of 75 mg Dabigatran coadministered with a morning dose of multiple dose (LD) ticagrelor.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dabigatran: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
          <population>Pharmacokinetic (PK) set defined as all subjects of Part 3 who received at least 1 dose of trial medication and provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.47" spread="130"/>
                    <measurement group_id="O2" value="61.30" spread="42.9"/>
                    <measurement group_id="O3" value="49.11" spread="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Related Adverse Events</title>
        <description>The number of participants with drug related adverse events</description>
        <time_frame>From screening until the end-of-study examination</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220 mg - Part 1</title>
            <description>A single dose of Dabigatran etexilate 220 mg (2 capsules of 110 mg), using a washed blood test.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 180 mg - Part 1</title>
            <description>A single dose of Ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a washed blood test.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran 220 mg - Part 2</title>
            <description>A single dose of Dabigatran etexilate 220 mg (2 capsules of 110 mg), using a shed blood test.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 180 mg - Part 2</title>
            <description>A single dose of Ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a shed blood test.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran 75 mg - Part 3</title>
            <description>A single dose of Dabigatran etexilate 75 mg</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran + Ticagrelor - Part 3</title>
            <description>Ticagrelor coated tablets dosed for four days; 180 mg loading dose on day 1, 90 mg twice daily on day 2 and 3, 90 mg on day 4. Co-administered is a single dose of 75 mg Dabigatran etexilate on days 1 and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related Adverse Events</title>
          <description>The number of participants with drug related adverse events</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 to 10 days after last dosing</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate 220 mg - Part 1</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a washed blood test.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor 180 mg - Part 1</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a washed blood test.</description>
        </group>
        <group group_id="E3">
          <title>Dabigatran Etexilate 220 mg - Part 2</title>
          <description>A single dose of dabigatran etexilate 220 mg (2 capsules of 110 mg), using a shed blood test.</description>
        </group>
        <group group_id="E4">
          <title>Ticagrelor 180 mg - Part 2</title>
          <description>A single dose of ticagrelor coated tablets 180 mg (2 tablets of 90 mg), using a shed blood test</description>
        </group>
        <group group_id="E5">
          <title>Dabi 75 mg - Part 3</title>
          <description>A single dose of dabigatran etexilate (Dabi) 75 mg</description>
        </group>
        <group group_id="E6">
          <title>Multiple Dose Ticagrelor - Part 3</title>
          <description>Ticagrelor coated tablets dosed for four days; 180 mg loading dose on day 1, 90 mg twice daily on day 2 and 3, 90 mg on day 4. Co-administered is a single dose of 75 mg Dabigatran etexilate on days 1 and 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

